Nurix Therapeutics vs UroGen Pharma
UroGen Pharma reported revenue of $110 million in fiscal 2025, 1.3 times Nurix Therapeutics' $84 million in fiscal 2025. Nurix Therapeutics' revenue grew 54.0% in its latest year, and UroGen Pharma's grew 21.4%. Nurix Therapeutics had an operating margin of -340.2%, against -113.7% at UroGen Pharma. Free cash flow was −$263 million at Nurix Therapeutics and −$163 million at UroGen Pharma. Their fiscal years end in different months (November 30 and December 31), so the periods don't line up exactly.
Side by side
| Nurix Therapeutics | UroGen Pharma | |
|---|---|---|
| Latest fiscal year | FY2025, Nov 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $84M | $110M |
| Revenue growth | 54.0% | 21.4% |
| Revenue growth a year, last 5 years | 36.4% | 56.2% |
| Gross margin | — | 88.7% |
| Operating margin | −340.2% | −113.7% |
| Net margin | −314.9% | −139.8% |
| Free cash flow | −$263M | −$163M |
| Free cash flow margin | −313.7% | −148.2% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 29.1% | 12.2% |
| Last close | $15.48 | $26.18 |
| P/E at the last close | 6.7× | — |
| Insider trades, last 12 months | sold $4.2 million | sold $4.7 million |
| Piotroski F-score | — | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Nurix TherapeuticsUroGen Pharma
Operating margin
Percent of revenue
Nurix TherapeuticsUroGen Pharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Nurix TherapeuticsUroGen Pharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Nurix Therapeutics and UroGen Pharma pages.